
Citi lowered the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 1,810 GBp from 1,870 GBp and keeps a Buy rating on the shares. Published first on TheFly – the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| HKMPF | Hikma Pharmaceuticals | 22.00 | 1.89 | 9.39% |
| Name | Price | % Change | |
|---|---|---|---|
| $22.00 | +9.39% |

Citi lowered the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 1,810 GBp from 1,870 GBp and keeps a Buy rating on the shares. Published first on TheFly – the

Hikma Pharmaceuticals ( ($GB:HIK) ) has shared an announcement. Hikma Pharmaceuticals has appointed Rebecca (Becky) Hall as its new Chief Financial Officer and Executive Director, with her joining in the

An announcement from Hikma Pharmaceuticals ( ($GB:HIK) ) is now available. Hikma Pharmaceuticals will host a three-part educational investor seminar series to showcase its R&D strategy and capabilities across key

Hikma Pharmaceuticals ( ($GB:HIK) ) just unveiled an announcement. Hikma Pharmaceuticals disclosed that persons discharging managerial responsibilities, including Susan Ringdal, Julie Hill and Sam Park, have acquired additional ordinary shares

Barclays analyst James Gordon upgraded Hikma Pharmaceuticals (HKMPF) to Equal Weight from Underweight with a price target of 1,700 GBp, up from 1,350 GBp. The company’s execution shortfalls and earnings

Hikma Pharmaceuticals ( ($GB:HIK) ) has provided an announcement. Hikma Pharmaceuticals reported that, as of 31 August 2026, its issued share capital consists of 208,747,630 ordinary shares of 10 pence

The latest announcement is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals has completed the second and final tranche of its $250 million share repurchase programme, buying 6,062,420 ordinary

An announcement from Hikma Pharmaceuticals ( ($GB:HIK) ) is now available. Hikma Pharmaceuticals has disclosed a series of share-pledge transactions involving senior insiders, including Chief Executive Officer Said Darwazah, Executive

The latest announcement is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals has continued the second tranche of its $250 million share repurchase programme, buying back ordinary shares between

Hikma Pharmaceuticals ( ($GB:HIK) ) has issued an announcement. Hikma Pharmaceuticals has repurchased 564,063 ordinary shares over 10–14 August on the London Stock Exchange as part of the second tranche
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $4.57B | $1.13 | $1.72B | 0.72 | 12.32 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.